Table of Contents Table of Contents
Previous Page  131 / 398 Next Page
Information
Show Menu
Previous Page 131 / 398 Next Page
Page Background

126

Objectives:

We aim to determine the benefits of ICT in OSCC

therapy by performing a systematic review using the cumulative

meta-analysis technique.

Methods:

A literature search identified for RCTs compar-

ing OSCC patients who received ICT against those without.

Log-hazard ratio, and relative risk were used for comparison. Het-

erogeneity was determined using the I2 statistic package. Data

analysis was performed for endpoints including overall survival

(OS), disease-free survival (DFS), locoregional recurrence (LRR)

and distant metastasis (DM).

Findings:

27 randomised trials were eligible for analysis

(

n

= 2872 patients). The shortest median follow-up was 15 months

whereas the longest was 11.5 years. ICT does not improve OS

(HR = 0.947; 95% CI 0.85–1.05;

P

= 0.318), DFS (RR = 1.05;

95% CI 0.92–1.21;

P

= 0.462) and DM (RR = 0.626; CI 95%

0.361–1.086;

P

= 0.096) compared to locoregional treatment

alone. However, there was a significant improvement to LRR

(RR = 0.778; 95% CI 0.622–0.972;

P

= 0.027).

Conclusion:

There is no evidence ICT improves survival out-

comes for OSCC patients which can be effectively visualised

through a cumulative meta-analysis approach. However, ICT

reduces locoregional recurrence of OSCC, whichmay need further

verification.

http://dx.doi.org/10.1016/j.ijom.2017.02.439

Must we remove submandibular glands during neck

dissection in oral squamous cell carcinoma patients?

K.H. Lee

∗

, K.C. Chen, T.Y. Wong

Division of Oral and Maxillofacial Surgery, Department of

Stomatology, National Cheng Kung University Hospital, Tainan,

Chinese Taipei

Background:

During the past years, treatment of oral squamous

cell carcinoma (OSCC) patients including ablative surgery of the

tumour and neck dissection to remove possible metastatic lymph

nodes. In the past, we usually removed submandibular glands at the

same time during neck dissection procedure. Patient often suffered

from xerostomia after the ablative surgery.

Objectives:

However, in our experiences, submandibular gland

metastasis was rare. We could not help asking: “Could we spare

the gland during neck dissection procedure?” And if we plan to

replace present treatment policy, we must have enough evidence

to support our idea. But the true metastasis rate of submandibular

gland is still lack of research evidence by now.

Methods:

In this study, 146 OSCC patients treated in NCKU from

2013 to 2016 were included. All of them received neck dissection

unilaterally or bilaterally during ablative surgery. The pathological

reports of these patients were reviewed and statistic analysed.

Findings and Conclusion:

Hardly any submandibular gland

metastasis was recorded, even with level Ib neck lymph node

metastasis. Only two patients with very advanced tumour were

found with submandibular gland involvement. The result supports

our idea that submandibular gland sparing during neck dissection

in OSCC patients is feasible and may improve the life of quality

of our patients after ablative surgery.

http://dx.doi.org/10.1016/j.ijom.2017.02.440

A potential solution to immunosuppression of the tumour

microenvironment: results of a phase 1 clinical trial of

anti-OX-40 in head and neck squamous cell carcinoma

R. Leidner

∗

, M. Crittenden, M. Gough, B.A. Fox,

A.D. Weinberg, E.J. Dierks, R.B. Bell

Providence Cancer Center, Portland, OR, United States

Background:

Cancer immunotherapy utilises the host immune

system to attack tumour cells by an activated immune response.

Head and neck SCC (HNSCC) release suppressive factors that

impair the immune system. OX40 is a potent costimulatory path-

way that when triggered can enhance T-cell memory, proliferation

and antitumour activity in patients with metastatic cancer.

Objectives:

To determine the maximum tolerated dose, toxicity,

immunologic activity, and potential clinical activity following one

cycle of anti-OX40 treatment.

Methods:

Participants received a single cycle of anti-OX40 given

intravenously on days one, three and five. There were three cohorts

of 10 patients each. Patients in cohort 1 received one cycle of

0.1 mg/kg; cohort 2, 0.4 mg/kg; and cohort 3, 2 mg/kg of the mAb.

Tumour tissues and peripheral blood are collected during resection

for measurements of tumour infiltrating immune cell populations

using flow cytometry and immunohistochemistry that may corre-

late with changes induced by anti-OX40 administration.

Results:

The toxicity profile was mild. Of the 30 patients treated,

12 patients displayed regression of individual tumour deposits

in lung, subcutaneous sites or lymph nodes; and six others had

stable metastatic disease for up to one year after anti-OX40 treat-

ment. Immunologic changes were observed at all dose levels with

significant proliferation of CD4+ and CD8+ central and effector

memory T-cell populations in both the tumour microenvironment

and circulation.

Conclusion:

There is significant expression of OX40 in the TIL

of patients with HNSCC. Furthermore, we noted co-expression of

OX40 with PD1 and CTLA-4 in a majority of tumour specimens,

especially within the T-reg population.

http://dx.doi.org/10.1016/j.ijom.2017.02.441

Global incidence of oral and oropharyngeal cancer in young

adults: a systematic review

F. Leusink

∗

, F. Leusink, A. Hussein, M. Helder, H. de Vet,

T. Forouzanfar

Department of Oral and Maxillofacial Surgery and Oral

Pathology, University Hospital Vrije Universiteit

Amsterdam/ACTA, Amsterdam, The Netherlands

Background:

Oral and oropharyngeal squamous cell carcinoma

(OOPSCC) is typically regarded as a disease of elderly people.

However, increasing numbers of patients worldwide with OOP-

SCC at a younger age (40–45 years) have been reported recently.

Objectives:

This systematic reviewbrings together 77 studies con-

ducted over four decades to look at geographical variations and

trends worldwide in incidence of OOPSCC in young adults.

Methods:

The authors searched PubMed and Google scholar

databases from 1975 to June 2016. Studies were included if they

reported incidence rate of oral and oropharynx cancer separately

for age cut-off less than 45 years.